Logo image of NEPH

NEPHROS INC (NEPH) Stock Fundamental Analysis

NASDAQ:NEPH - Nasdaq - US6406714005 - Common Stock - Currency: USD

1.5267  +0.04 (+2.46%)

Fundamental Rating

3

Taking everything into account, NEPH scores 3 out of 10 in our fundamental rating. NEPH was compared to 129 industry peers in the Machinery industry. NEPH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, NEPH is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NEPH had negative earnings in the past year.
NEPH had a negative operating cash flow in the past year.
In the past 5 years NEPH always reported negative net income.
In the past 5 years NEPH reported 4 times negative operating cash flow.
NEPH Yearly Net Income VS EBIT VS OCF VS FCFNEPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2M -4M -6M

1.2 Ratios

The Return On Assets of NEPH (-8.94%) is worse than 76.80% of its industry peers.
NEPH's Return On Equity of -11.37% is on the low side compared to the rest of the industry. NEPH is outperformed by 73.60% of its industry peers.
Industry RankSector Rank
ROA -8.94%
ROE -11.37%
ROIC N/A
ROA(3y)-34.55%
ROA(5y)-31.77%
ROE(3y)-62%
ROE(5y)-59.43%
ROIC(3y)N/A
ROIC(5y)N/A
NEPH Yearly ROA, ROE, ROICNEPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300 -400

1.3 Margins

NEPH's Gross Margin of 61.04% is amongst the best of the industry. NEPH outperforms 98.40% of its industry peers.
NEPH's Gross Margin has been stable in the last couple of years.
NEPH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.04%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.96%
GM growth 5Y0.97%
NEPH Yearly Profit, Operating, Gross MarginsNEPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100 -150

More info and screens

5

2. Health

2.1 Basic Checks

NEPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NEPH has been increased compared to 1 year ago.
The number of shares outstanding for NEPH has been increased compared to 5 years ago.
NEPH has a better debt/assets ratio than last year.
NEPH Yearly Shares OutstandingNEPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
NEPH Yearly Total Debt VS Total AssetsNEPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

2.2 Solvency

NEPH has an Altman-Z score of -13.41. This is a bad value and indicates that NEPH is not financially healthy and even has some risk of bankruptcy.
NEPH's Altman-Z score of -13.41 is on the low side compared to the rest of the industry. NEPH is outperformed by 88.00% of its industry peers.
NEPH has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
NEPH has a Debt to Equity ratio of 0.00. This is amongst the best in the industry. NEPH outperforms 84.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.41
ROIC/WACCN/A
WACC10.6%
NEPH Yearly LT Debt VS Equity VS FCFNEPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M 10M

2.3 Liquidity

NEPH has a Current Ratio of 6.95. This indicates that NEPH is financially healthy and has no problem in meeting its short term obligations.
NEPH's Current ratio of 6.95 is amongst the best of the industry. NEPH outperforms 95.20% of its industry peers.
A Quick Ratio of 4.02 indicates that NEPH has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 4.02, NEPH belongs to the best of the industry, outperforming 92.80% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.95
Quick Ratio 4.02
NEPH Yearly Current Assets VS Current LiabilitesNEPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

4

3. Growth

3.1 Past

NEPH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.63%, which is quite impressive.
Looking at the last year, NEPH shows a decrease in Revenue. The Revenue has decreased by -0.03% in the last year.
The Revenue has been growing by 20.13% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)52.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
Revenue 1Y (TTM)-0.03%
Revenue growth 3Y18.48%
Revenue growth 5Y20.13%
Sales Q2Q%-5.99%

3.2 Future

The Earnings Per Share is expected to grow by 35.29% on average over the next years. This is a very strong growth
Based on estimates for the next years, NEPH will show a small growth in Revenue. The Revenue will grow by 4.77% on average per year.
EPS Next Y72.8%
EPS Next 2Y46.15%
EPS Next 3Y35.29%
EPS Next 5YN/A
Revenue Next Year-6.32%
Revenue Next 2Y1.11%
Revenue Next 3Y4.77%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
NEPH Yearly Revenue VS EstimatesNEPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M
NEPH Yearly EPS VS EstimatesNEPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -0.2 -0.4 -0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

NEPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
NEPH is valuated quite expensively with a Price/Forward Earnings ratio of 74.84.
Based on the Price/Forward Earnings ratio, NEPH is valued a bit more expensive than the industry average as 68.80% of the companies are valued more cheaply.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.68, NEPH is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 74.84
NEPH Price Earnings VS Forward Price EarningsNEPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NEPH Per share dataNEPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

NEPH's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as NEPH's earnings are expected to grow with 35.29% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.15%
EPS Next 3Y35.29%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NEPH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEPHROS INC

NASDAQ:NEPH (2/21/2025, 8:00:01 PM)

1.5267

+0.04 (+2.46%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryMachinery
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)02-26 2025-02-26/amc
Inst Owners44.7%
Inst Owner Change9.97%
Ins Owners11.86%
Ins Owner Change2.53%
Market Cap16.09M
Analysts82.5
Price Target5.1 (234.05%)
Short Float %0.05%
Short Ratio0.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend5.83
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)50.98%
Min EPS beat(2)-96.08%
Max EPS beat(2)198.04%
EPS beat(4)2
Avg EPS beat(4)4.41%
Min EPS beat(4)-135.29%
Max EPS beat(4)198.04%
EPS beat(8)4
Avg EPS beat(8)2.29%
EPS beat(12)6
Avg EPS beat(12)-18.18%
EPS beat(16)8
Avg EPS beat(16)-12.25%
Revenue beat(2)0
Avg Revenue beat(2)-9.42%
Min Revenue beat(2)-17.42%
Max Revenue beat(2)-1.43%
Revenue beat(4)0
Avg Revenue beat(4)-10.68%
Min Revenue beat(4)-17.42%
Max Revenue beat(4)-1.43%
Revenue beat(8)2
Avg Revenue beat(8)-4.18%
Revenue beat(12)3
Avg Revenue beat(12)-6.31%
Revenue beat(16)4
Avg Revenue beat(16)-5.24%
PT rev (1m)0%
PT rev (3m)5.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)50%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.88%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.62%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 74.84
P/S 1.19
P/FCF N/A
P/OCF N/A
P/B 1.97
P/tB 2.36
EV/EBITDA N/A
EPS(TTM)-0.09
EYN/A
EPS(NY)0.02
Fwd EY1.34%
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS1.29
BVpS0.78
TBVpS0.65
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.94%
ROE -11.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.04%
FCFM N/A
ROA(3y)-34.55%
ROA(5y)-31.77%
ROE(3y)-62%
ROE(5y)-59.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.96%
GM growth 5Y0.97%
F-Score4
Asset Turnover1.3
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 83.33%
Cap/Sales 0.96%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.95
Quick Ratio 4.02
Altman-Z -13.41
F-Score4
WACC10.6%
ROIC/WACCN/A
Cap/Depr(3y)30.35%
Cap/Depr(5y)42.07%
Cap/Sales(3y)0.77%
Cap/Sales(5y)1.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
EPS Next Y72.8%
EPS Next 2Y46.15%
EPS Next 3Y35.29%
EPS Next 5YN/A
Revenue 1Y (TTM)-0.03%
Revenue growth 3Y18.48%
Revenue growth 5Y20.13%
Sales Q2Q%-5.99%
Revenue Next Year-6.32%
Revenue Next 2Y1.11%
Revenue Next 3Y4.77%
Revenue Next 5YN/A
EBIT growth 1Y41.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y38.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.67%
OCF growth 3YN/A
OCF growth 5YN/A